Hollow Manganese Dioxide-Based Nanodelivery System for Paclitaxel to Enhance Therapeutic Efficacy in Breast Cancer Treatment

Breast cancer stands as the most frequently diagnosed cancer among women globally, with paclitaxel (PTX) being a prevalent drug in its treatment regimen. However, the poor solubility of PTX necessitates the use of substantial amounts of cosolvent in its injectable form, potentially triggering severe allergic reactions in clinical applications. To enhance the efficacy of PTX against breast cancer, here we report a novel hyaluronic acid (HA) modified and PTX-loaded hollow manganese dioxide (H-MnO₂) (PTX@H-MnO₂@HA) nanodelivery system for targeted therapy. In vitro cellular experiments have demonstrated that PTX@H-MnO₂@HA exhibits exceptional cellular uptake capability, outperforming nontargeted nanoparticles by a magnitude of two, showing significant antitumor effects. Cell viability assays have revealed that at the same drug concentration, PTX@H-MnO₂@HA displays 20% greater cytotoxicity against tumor cells compared to the free drug, further substantiating its potent tumoricidal activity. In vivo animal experiments have corroborated the outstanding tumor-targeting ability of this nanosystem in mice, where it significantly inhibits tumor growth and demonstrates excellent magnetic resonance imaging performance at the tumor site with fewer toxic effects and side effects on normal organs. The synergistic multifunctional effects endow the PTX@H-MnO₂@HA platform with robust tumor-suppressive capabilities both in vitro and in vivo, offering a highly promising new strategy for tumor therapy. It holds the potential to pioneer novel avenues in clinical tumor treatment.